Aclaris Q3 10-Q: $204.6M Cash, $59.8M Nine-Month Loss, $116M Raised Via ATM
ACRS sits 72% above its 52-week low of $2.1.
Summary
Aclaris closed Q3 with $204.6 million in cash and securities after raising $116.2 million net through its ATM during 2026, enough to fund its clinical programs despite a nine-month net loss of $59.8 million and a share count that rose from 120.5 million to 150.8 million.
Key Events · Earnings and Guidance · ACRS
-
Q3 Loss Widens on Clinical Spend
Net loss for Q3 2026 was $18.5 million ($0.12 per share), versus $14.6 million a year earlier; the nine-month loss reached $59.8 million versus $45.1 million.
-
Cash Position Grows to $204.6M
Cash, cash equivalents and marketable securities totaled $204.6 million at September 30, 2026, up from $147.7 million at December 31, 2025; management states this funds operations for more than 12 months.
-
ATM Raises $116.2M Net in 2026
At-the-market sales totaled 18.4 million shares for $59.8 million gross in March, 7.3 million shares for $40.2 million in July and 3.6 million shares for $20.0 million in September, netting $116.2 million.
-
October Offering Adds $46.7M Net
The October 2026 offering closed with 7,785,714 shares at $3.50 and pre-funded warrants for 6,500,000 shares at $3.49999 per warrant, for $50.0 million gross and $46.7 million net.
Analysis · ACRS · Life Sciences
The balance sheet is the headline: cash and marketable securities stood at $204.6 million on September 30, up from $147.7 million at year-end, after the company pulled in $116.2 million net from at-the-market share sales during 2026 and another $46.7 million net from the October offering. That funding carries the bosakitug Phase 2 atopic dermatitis readout expected in Q4 2026 and the ATI-052 Phase 2b in eosinophilic esophagitis planned for early 2027 without a near-term financing. Dilution is the cost: shares outstanding climbed from 120.5 million to 150.8 million in nine months, and the loss widened to $59.8 million from $45.1 million as ATI-052 and ATI-9494 development spending ramped. No going-concern language appears — management says cash covers more than 12 months.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACRS was trading at $3.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $559.5M. The 52-week trading range was $2.10 to $6.60. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.